Développement de virus HSV-1 (virus de l herpes simplex de type 1) oncolytiques ciblés pour traiter les carcinomes hépatocellulaires Aldo Decio Pourchet To cite this version: Aldo Decio Pourchet. Développement de virus HSV-1 (virus de l herpes simplex de type 1) oncolytiques ciblés pour traiter les carcinomes hépatocellulaires. Sciences agricoles. Université Claude Bernard - Lyon I, 2010. Français. <NNT : 2010LYO10155>. <tel-00603671> HAL Id: tel-00603671 https://tel.archives-ouvertes.fr/tel-00603671 Submitted on 27 Jun 2011 HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
,
,
/
μ
1,00E+08 1,00E+07 1,00E+06 1,00E+05 Hepatocytes ANGPTL3 Pfu totales 1,00E+04 1,00E+03 1,00E+02 1,00E+01 Huh7 ANGPTL3 Hep3B ANGPTL3 1,00E+00 0 10 20 30 40 50 60 Heures post infection m.o.i. 0,02 140 Luminescence (photons/sec) 120 100 80 60 40 20 0 0 10 20 30 40 50 60 Heures post infection m.o.i. 0,02 Hepatocytes ANGPTL3 Huh7 ANGPTL3 Hep3B ANGPTL3
1,00E+08 1,00E+07 1,00E+06 Pfu totales 1,00E+05 1,00E+04 1,00E+03 1,00E+02 1,00E+01 Hepatocytes hcmv Huh7 hcmv Hep3B hcmv 1,00E+00 0 10 20 30 40 50 60 Heures post infection m.o.i. 0,02 4500 Luminescence (photons/sec) 4000 3500 3000 2500 2000 1500 1000 500 0-500 0 10 20 30 40 50 60 Heures post infection m.o.i. 0,02 Hepatocytes hcmv Huh7 hcmv Hep3B hcmv
1,00E+05 Luminescence (photons/sec) 1,00E+04 1,00E+03 1,00E+02 1,00E+01 hcmv ADH6 AFP ANGPTL3 9xHRE 9xHRE + DFO 1,00E+00 2 4 6 8 Heures post infection m.o.i. 5
,
, (
.
1 Molecular Virology Laboratory, Hellenic Pasteur Institute, Athens, Greece. 4 Laboratory of Surgical Research, Medical School of Athens, Hippokration Hospital, Athens, Greece. 5 2 nd Department of Internal Medicine, Medical School of Athens, Hippokration Hospital, Athens, Greece.
*Corresponding Author: Penelope Mavromara Molecular Virology Laboratory, Hellenic Pasteur Institute, 127 V. Sofias ave., 11521, Athens, Greece, e-mail: (penelopm@pasteur.gr), tel: +302106478877 The first and second author contributed equally to this work and should be regarded as joint first authors
6
5
5
7 7 7
6. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocytemacrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.j Clin Oncol. 2009;27:5763-71.
21. Hoffmann D, Wildner O. Restriction of adenoviral replication to the transcriptional intersection of two different promoters for colorectal and pancreatic cancer treatment. Mol Cancer Ther. 2006;5:374-381. 22. Bortolanza S, Bunuales M, Otano I, et al. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther. 2009;17:614-622.
NM_001134
5 5
4 5 7 4
Tumour/Normal Expression Ratio (TPM) ApoB 26 ITIH3 15 CYP2C8 14 ITIH1 9 AFP 6 ANGPTL-3 5 ADH6 5 FGB 5 VTN 4